Book Online
Please choose which location you would like to make an appointment for.
Australia has become one of the world's most attractive destinations for clinical research, offering international sponsors access to experienced investigators, high-quality clinical data and efficient study startup pathways.
For pharmaceutical companies, biotechnology organisations, medical device manufacturers and Contract Research Organisations (CROs), Australia provides a compelling environment to conduct ophthalmic clinical trials while maintaining internationally recognised research standards.
Australia is recognised for its streamlined clinical trial approval pathways.
Compared with many international jurisdictions, studies can often commence more rapidly through established ethics and governance processes, helping sponsors reduce development timelines and accelerate participant enrolment.
For organisations seeking to bring new therapies and technologies to market, these efficiencies can provide a meaningful advantage during clinical development. Average start-up times for phase 1 or 2 trials in Australia is 8-12 weeks.
Australian clinical research is conducted under internationally recognised Good Clinical Practice (GCP) standards and robust regulatory oversight.
This provides sponsors with confidence that study outcomes can support global development programs and regulatory submissions.
One of Australia's most significant advantages for international sponsors is the Research and Development Tax Incentive (RDTI) program.
Australia's R&D framework has helped establish the country as a preferred destination for pharmaceutical, biotechnology and medical device research by providing financial incentives for eligible research and development activities conducted within Australia.
Eligible biotech companies can access up to a 43.5% Australian Government Research and Development Incentive. This rebate is a cash refund direct to the Sponsor.
For international sponsors entering the Australian market, selecting the right research partner is an important part of successful study delivery.
Ophthalmic Clinical Trials suppor sponsors and CROs through all stages of ophthalmic clinical research, from feasibility and participant recruitment through to specialist assessments and study delivery.
With experience across dry eye disease, contact lens research, ocular surface disorders, ophthalmic medical devices and ocular safety monitoring, our team provides local expertise and practical support for studies conducted in Australia.
If you are considering Australia for an upcoming ophthalmic clinical trial, we would welcome the opportunity to discuss your protocol requirements, recruitment objectives and site feasibility needs.